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Background: Numerous proteins have been proposed as virulence factors for the gram negative gastric bacterium
Helicobacter pylori but only for a few this has unequivocally been demonstrated. The aim of the current study was
to evaluate the association of the putative virulence factors tnpA and tnpB (no cagA) with H. pylori associated
gastroduodenal diseases.
Methods: A PCR based assay was used to determine the presence of the tnpA and tnpB genes, as well as of cagA,
in 360H. pylori strains isolated from H. pylori infected patients.
Results: Of 360H. pylori culture positive patients (196 men, 164 women; average age 42.1 years (range 17–73), 95
had gastritis, 92 had gastric ulcers, 108 had duodenal ulcers, and 65 had gastric cancer. Using the gastritis group as
a reference a significantly aberrant gene distribution was observed for the tnpA (Relative risk: 1.45; 95% CI 1.04-1.93),
the cagA (Relative risk: 1.81; 95% CI 1.44-2.29), but not the tnpB gene in the gastric cancer group.
Conclusions: The increased incidence of the tnpA gene in gastric cancer patients suggests a role of the tnpA gene
in the development of H. pylori induced gastric cancer.
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Helicobacter pylori is the most prevalent pathogenic micro-
organism colonizing the gastric mucosa of humans. Infec-
tion rates range between 85-95% in developing countries
and 30-50% in developed countries [1]. Colonization al-
ways results in acute gastritis and chronic gastritis when
left untreated [2]. Additional complications such as gastric
ulcers (GU), duodenal ulcers (DU), or gastric cancer (GC)
may develop in some of these H. pylori infected patients
[3]. The outcome of the infection is determined by both
the duration of infection and environmental, host, and bac-
terial factors [4]. H. pylori strains display extensive genetic
variability with considerable variation in the presence of
virulence factors, which is thought to cause the many dif-
ferent clinical presentations of H. pylori infections [5-7].
The CagA protein is a commonly accepted virulence factor
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reproduction in any medium, provided the orpresence of the cag (cytotoxin-associated gene) pathogen-
icity island (cagPAI) [4]. Patients infected with H. pylori
strains that carry cagA have a higher risk for developing
peptic ulcer and gastric cancer [8]. Other virulence deter-
minants located on the cagPAI such as cagE, cagG, cagH,
cagI, cagL, and cagM are required for cagPAI mediated
NF-κB induction, and cagT and cagY are required for the
formation of a needle-like structure that serves to inject
cagA into the host cell [9,10]. Although these factors play a
critical role in the pathogenesis of H. pylori, their associ-
ation with specific disease outcomes is not as obvious as
with cagA. It has been reported that in some H. pylori
strains the cagPAI is split into two separate regions due to
the integration of the IS605 insertion sequence [10]. The
putative IS605 transposases (tnpA and tnpB) that can me-
diate this cagPAI disruption [10] might affect the virulence
of H. pylori [11], but the exact biological role and clinical
relevance of these two determinants is poorly studied. Iran
is a developing country with a high prevalence of H. pylori,
among both symptomatic and asymptomatic individuals,
and with a prevalence as high as 95% in the northern parttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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an even higher rate of H. pylori induced peptic ulcer dis-
ease and gastric cancers [14]. This makes it an ideal geo-
graphically confined region to study the effect of genetic
variation of this gastric pathogen on infection associated
disorders. In this study we determined associations of the
presence of tnpA and tnpB and clinical manifestations of
H. pylori infections in patients from the North of Iran.
Methods
Patients
All patients suspect of a H. pylori infection that visited
the Tooba Medical Center, in Sari, Iran for endoscopic
examination between May 2008 and October 2010 were
invited to participate in this study. Patients participating
in this study underwent routine gastroscopic examination.
The standard number of gastric biopsy samples for pa-
tients’ suspect of Helicobacter infection was obtained for
routine culture and histological investigations and no
extra samples were taken for this study. One of the gastric
biopsy samples was sent to the pathology lab where it was
tested by routine histopathological techniques and evalu-
ated by standard criteria. Histology grading was performed
by the updated Sydney criteria [15]. The other routinely
obtained biopsy samples were used for microbiological
culture and Rapid Urease Test (RUT), as described below.
Ages below 16 years were excluded due to ethical consid-
erations. Also antibiotic use within four months prior to
endoscopy, or use of anti-secretory drugs within one
month before endoscopy were used as exclusion criteria.
This study was approved by the local ethics committee of
Tarbiat Modares University, as no extra biopsy samples
were needed for this study and that the obtained data
could not be traced back to the patient level.
Microbiological analysis
One of the biopsy samples was routinely tested by the
gastroenterologist by Rapid Urease Test; and if positive a
second sample was obtained and placed in 200 μl sterile
thioglycolate (Merck, Germany) broth and then immedi-
ately shipped to the diagnostic laboratory for routine cul-
ture. Upon arrival in the microbiology lab this sample was
immediately grinded and 100 μl of the resultant homogen-
ate was inoculated on a Colombia agar (Merck, Germany)
plate supplemented with 7% defibrinated sheep blood
(Jihad Daneshgahi, Tehran, Iran), 10% Fetal Calf Serum
(FCS) and antibiotics (DENT, Supplement, Oxoid) [15].
Plates were incubated at 37°C, in 10% CO2 conditions
provided by incubator (Binder, USA) and high humidity
until typical H. pylori colonies appeared or for a maximum
of 7 days if no suspect colonies were observed. Colony
shape, morphology in microscopic examination, routine
biochemical tests such as urease, catalase and oxidase tests
were performed for identification of H. pylori strains.DNA extraction and PCR
Bacterial DNA was extracted from single colonies of H.
pylori using a commercially available kit (ExiPrep™ Bac-
teria Genomic DNA Kit, Bioneer, Daejeon, South Korea).
Genotyping was performed by PCR, using specific primers
for cagA, tnpA and tnpB as previously described (Table 1).
In addition a glmM PCR (Table 1) was carried out [16],
both as an additional control for H. pylori identification
and quality check of the isolated DNA (positive PCR
control). The PCR amplified fragments were size sepa-
rated on 2% agarose gel (Sinagene, Tehran, Iran) and
the ethidium bromide stained DNA was visualized using
UV illumination.Statistical analysis
The chi-square and Fisher exact test was used to test for
the association between patient demographics, H. pylori
genotypes, and disease groups. A P value of less than 0.05
was accepted as statistically significant. Microsoft Excel
2010 was used to calculate the P values, odds ratio (OR)
and 95% confidence interval (95% CI).Results
376 patients suspect for H. pylori infection (positive RUT
test) were enrolled, but H. pylori specific growth was not
observed from the biopsy specimen in 16 of them. The
remaining 360 patients that were H. pylori culture positive
(96%) comprised 95 patients with gastritis (G), 92 with gas-
tric ulcer (GU), 108 with duodenal ulcer, and 65 with gas-
tric cancer (GC) (Table 2). The average age was 42.1 years
(range 17 to 73 year) and there were slightly more men
(n = 196) than women (n = 164). Detailed demographic
data of dyspeptic patients according to age, disease symp-
toms, and histological findings are shown in Table 2. There
were slightly more males with duodenal ulcers, and less
with gastric ulcers, but there were no statistically signifi-
cant associations between age, gender, histopathological
findings, and H. pylori associated disease groups.
Table 2 Detailed demographic data of dyspeptic patients according to the age and pathologic findings
Disease type Sample size Male (%) Pathology findings Age range detailed data for each disease groups
<30 31-40 41-50 51-60 >60
G 95 51 (53.6)
Mild (n = 14) 6 7 1 0 0
Moderate (n = 67) 33 26 6 2 0
Atrophic (n = 20) 8 5 6 1 0
GU 92 38 (41.3)
Mild (n = 15) 2 3 4 4 2
Moderate (n = 84) 7 12 21 11 33
Atrophic (n = 13) 0 2 2 6 3
DU 108 72 (66)
Mild (n = 23) 4 5 5 6 3
Moderate (n = 57) 6 18 13 12 8
Atrophic (n = 23) 6 7 7 6 4
GC 65 35 (53.8)
Mild (n = 7) 0 0 1 2 4
Moderate (n = 47) 0 0 17 16 14
Atrophic (n = 11) 0 0 6 1 4
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The overall prevalence of the tnpA, tnpB, and cagA genes
were 47.5%, 13.1%, and 59.2%, respectively, and the preva-
lence of these genes in the four disease groups is listed in
Table 3. No significant associations were observed be-
tween the presence of the tnpA, tnpB and cagA genes and
histological findings. Statistical analysis did however reveal
a significant association between the presence of the cagA
gene and GC [Relative risk: 1.81; 95% CI 1.44-2.29], and a
weak, but significant correlation was observed between
the presence of the cagA gene and DU [Relative risk: 1.30;
95% CI 1.01-1.69] and the tnpA gene with GC [Relative
risk: 1.45; 95% CI 1.04-1.93] (Table 3). No significant
association was observed for tnpB and gastroduodenal
diseases.
Discussion and conclusions
To our knowledge, this is the largest study (n = 360) in-
vestigating the distribution of the H. pylori virulence
tnpA, tnpB and cagA in dyspeptic patients. In the first
study on tnpA and tnpB by Matter et al. [11], 63% of
215 clinical H. pylori isolates were tnpA positive and
13.5% were positive for tnpB, with a statistically signifi-
cant association between peptic ulcer disease (PUD) and
tnpA positive strains. This association was not apparent
for tnpB. In the current study there was a similarTable 3 Prevalence of the tnpA, tnpB, and cagA genes in the f
Disease groups tnpA
Positives Relative risk 95% CI Po
Gastritis (n = 95) (Control group) 40 (42.1%) Reference 16
Gastric ulcer (n = 92) 48 (52.2%) 1.23 0.97-1.61 10
Duodenal ulcer (n = 108) 44 (40.7%) 0.96 0.69-1.34 11
Gastric cancer (n = 65) 39 (60.0%) 1.45 1.04-1.93 10prevalence of tnpA and tnpB [171/360; 47.5% and 47/
360; 13.1%, for tnpA and tnpB respectively], and a simi-
lar association between cagA and gastric cancer patients
as observed in a preliminary study by Matter et al. [11].
Unfortunately in their study the associations of tnpA
and tnpB with H. pylori associated disease types were
not determined. In a more recent but smaller study
Matter et al. investigated associations between presence
of tnpA and tnpB and gastric cancer in Brazilian patients
with gastric cancer (n = 34) and gastritis (n = 34) [17].
The patient population studied here is from the North
of Iran (state of Mazandaran), and has been reported to
not only have a very high H. pylori infection rate but
also a very high rate patients suffering from H. pylori
induced disease [18] This high H. pylori prevalence facil-
itates the collection of a large number of strains from a
well defined, small geographical region and this facilitated
a study on the putative association between the presence
of tnpA/B and the clinical outcome of the H.pylori infec-
tion. The prevalence of tnpA and tnpB among gastric
cancer and gastritis patients in the Iranian population in-
cluded in the current study was 42.1% and 60.0% for tnpA,
and 16.8% and 15.4% for tnpB, respectively, which, again,
was comparable to the findings in the Brazilian population
with gastric cancer or gastritis (29.4% and 73.5% for tnpA;
and 2.9% and 5.9% for tnpB, respectively). Kersulyte et al.our patient groups
tnpB cagA
sitives Relative risk 95% CI Positives Relative risk 95% CI
(16.8%) Reference 45 (47.4%) Reference
(10.9%) 0.64 0.30-1.34 45 (48.9%) 1.03 0.76-1.39
(10.2%) 0.59 0.29-1.22 67 (62%) 1.30 1.01-1.69
(15.4%) 0.91 0.44-1.88 56 (86.2%) 1.81 1.44-2.29
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gastric cancer strains than in gastritis strains (9/14 (46%)
versus 15/45 (33%), respectively). Although the observed
associations between tnpA and gastric cancer are similar
in the populations in Peru, Brazil and Iran [11,19], there
are striking differences for associations of cagA with dis-
ease status between these populations. We observed a
clear association between the presence of cagA and gastric
cancer in the Iranian population, while Matter et al. [11]
did not observe such an association in Brazil. While most
studies report an association between the presence of
cagA and gastric cancer some studies do not observe this
association [20,21]. In this particular case it may be due to
the low number of patients included in their study (n = 64;
versus 160 in our study). After the recognition of H. pylori
as an important gastric pathogen [21], many attempts
have been made to identify H. pylori virulence factors pre-
dicting clinical outcome as this might assist physicians in
prediction of disease progression [22]. When using the
gastritis group as controls for gene distribution we ob-
served an increased prevalence of the tnpA and cagA
genes in the gastric cancer group. To our knowledge this
study represents the largest cohort tested thus far for
the prevalence of tnpA for an association with the vari-
ous H. pylori infection associated disease groups. While
it is tempting to conclude from the increased prevalence
of tnpA and cagA in the gastric cancer group that these
genes may serve as useful biomarkers for gastric cancer
one cannot draw that conclusion from a cross-sectional
study like ours. Also our study design did not include a
questionnaire on the disease history of our patients and
hence we are unable to correlate clinical symptoms such
as bleeding, reflux, abdominal pain etc. with the pres-
ence/absence of these virulence factors. A large pro-
spective cohort study would be required to establish
reliable positive and negative predictive values of these
putative biomarkers. Due to the long time between in-
fection and cancer development such a study would re-
quire long follow-up times, and since only few infected
individuals develop cancer a large study cohort would be
required. In addition there are ethical issues with such a
study as the hypothesis to be tested is that patients in-
fected with tnpA positive H. pylori strains are more prone
to developing gastric cancer than patients infected with
tnpA negative strains. In order to test this hypothesis one
must establish the presence of the tnpA+/− H. pylori strain
at the start of the study while refraining from eradication
of these potentially carcinogenic strains for a long period
of time. In spite of the shortcomings of our cross-
sectional study it provides strong indications for the clin-
ical relevance of the tnpA gene of H. pylori strains isolated
from the Iranian population where the prevalence of H.
pylori is relatively high [13] and this high prevalence is
coupled to a high incidence of H. pylori induced pepticulcer disease and gastric cancers [23]. In conclusion tnpA
but not tnpB is clearly associated with a more severe dis-
ease outcome of Hc pylori infections. As such tnpA could
be a valuable novel biomarker but clearly further studies
are required to confirm these results especially since at
present no obvious biological explanation for a GC indu-
cing function of this putative transposase can be provided.
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